glp-1 manufacturers enter a turf war New federal agreement lowers GLP-1

Description

Heres a recap of what weve covered: Orforglipron is a daily oral GLP-1 medication made by Eli Lilly that was approved by the FDA for weight loss and management under the brand name Foundayo in April 2026

Nutritional deficits for the infant

If finalized, it would formally close their pathway to compound semaglutide and tirzepatide from bulk substances

Improved Formulations and Delivery Methods Other advancements include longer-acting formulations that may eventually require less frequent dosing, improved delivery methods that enhance comfort and convenience, and combination approaches that pair GLP-1 therapy with complementary treatments

Tirzepatide does not require dose adjustment for mild to moderate kidney disease, potentially providing consistent efficacy across different stages of renal function